Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2020

View Archived Issues

OyaGen to develop OYA-1 for the treatment of coronaviruses

Denali studies DNL-343 in healthy volunteers in new phase I trial

Researchers present phase II data for tafoxiparin in women in labor

Aclaris initiates phase IIa study of ATI-450 with methotrexate for moderate to severe RA

Chlorotoxin-CAR T cells specifically targeting glioblastomas shows preclinical antitumor activity

Poseida Therapeutics initiates phase I study of P-PSMA-101 CAR-T cells

Patient enrollment ongoing in phase I study of CS-3002

Phase IIb ARISE study of padsevonil does not reach statistical significance for primary endpoints

Anti-POTEF autoantibodies as new biomarker in primary ovarian insufficiency

NPSR1 as a novel nonhormonal target in endometriosis

First-in-human data for (R,R)-penehyclidine fumarate

New approach to cancer immunotherapy identified

FDA clears IND for phase I/II trial of Adaptive Phage Therapeutics' PhageBank

Researchers develop murine model of CMV infection in pregnancy

See in 3D

PharmaMar reports promising in vitro study results with Aplidin against coronavirus HCoV-229E

University of Edinburgh discloses new cyclophilin inhibitors

New glutaminyl cyclase inhibitors patented by Academia Sinica, NHRI

Daewoong Pharmaceutical describes dual BTK/ITK inhibitors

Merck KGaA discovers Bruton tyrosine kinase inhibitors

New pantetheinase inhibitors presented by Boehringer Ingelheim

Janssen collaborates with Beth Israel Deaconess on preventive vaccine candidate for COVID-19

Algernon to seek funding from COVID-19 Therapeutic Accelerator program for repurposed drug

Preclinical data show PAT-DX1 crosses blood-brain barrier via ENT2 pathway

Japanese approval for new Ozempic SD subcutaneous injection formulation

Kevzara enters global clinical program for use in severe COVID-19 infection

Trial of darunavir/cobicistat and hydroxychloroquine to reduce transmission of SARS-CoV-2 begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...